Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Oct;65(10):1325-9.
doi: 10.1136/ard.2005.050187. Epub 2006 Mar 15.

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study

D Khanna  1 , D E Furst, R D Hays, G S Park, W K Wong, J R Seibold, M D Mayes, B White, F F Wigley, M Weisman, W Barr, L Moreland, T A Medsger Jr, V D Steen, R W Martin, D Collier, A Weinstein, E V Lally, J Varga, S R Weiner, B Andrews, M Abeles, P J Clements
Affiliations
Randomized Controlled Trial

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study

D Khanna et al. Ann Rheum Dis. 2006 Oct.

Abstract

Objective: To estimate minimally important differences (MIDs) in scores for the modified Rodnan Skin Score (mRSS) and Health Assessment Questionnaire-Disability Index (HAQ-DI) in a clinical trial on diffuse systemic sclerosis (SSc).

Participants and methods: 134 people participated in a 2-year, double-blind, randomised clinical trial comparing efficacy of low-dose and high-dose D-penicillamine in diffuse SSc. At 6, 12, 18 and 24 months, the investigator was asked to rate the change in the patient's health since entering the study: markedly worsened, moderately worsened, slightly worsened, unchanged, slightly improved, moderately improved or markedly improved. Patients who were rated as slightly improved were defined as the minimally changed subgroup and compared with patients rated as moderately or markedly improved.

Results: The MID estimates for the mRSS improvement ranged from 3.2 to 5.3 (0.40-0.66 effect size) and for the HAQ-DI from 0.10 to 0.14 (0.15-0.21 effect size). Patients who were rated to improve more than slightly were found to improve by 6.9-14.2 (0.86-1.77 effect size) on the mRSS and 0.21-0.55 (0.32-0.83 effect size) on the HAQ-DI score.

Conclusion: MID estimates are provided for improvement in the mRSS and HAQ-DI scores, which can help in interpreting clinical trials on patients with SSc and be used for sample size calculation for future clinical trials on diffuse SSc.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Khanna D, Clements P J, Furst D E, Chon Y, Elashoff R, Roth M D.et al Correlation of the degree of dyspnea with health‐related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 200552592–600. - PubMed
    1. Osoba D, King M. Meaningful differences. In: Fayers P, Hays RD, eds. Assessing quality of life in clinical trials. Oxford Press: New York, 2005244–257.
    1. Jaeschke R, Singer J, Guyatt G H. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 198910407–415. - PubMed
    1. van Walraven C, Mahon J L, Moher D, Bohm C, Laupacis A. Surveying physicians to determine the minimal important difference: implications for sample‐size calculation. J Clin Epidemiol 199952717–723. - PubMed
    1. Hays R D, Woolley J M. The concept of clinically meaningful difference in health‐related quality‐of‐life research. How meaningful is it? Pharmacoeconomics 200018419–423. - PubMed

Publication types